Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 20/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 20/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 20/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 20/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 20/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 20/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 20/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 20/20 | 0.51 |
| ▸ | KDR | P35968 | 16/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13310075 | 0.89 | KDR (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13310076 | 0.88 | KDR (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13310083 | 0.81 | SRC (0.53) | KDR | |
| SCHEMBL13310085 | 0.80 | AURKA (0.54) | KDR | |
| SCHEMBL20752915 | 0.73 | KDR (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20752916 | 0.73 | KDR (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20752891 | 0.73 | KDR (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13310046 | 0.71 | KDR (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20752888 | 0.71 | KDR (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20752892 | 0.71 | KDR (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN-CILAG (FR) | 2010-06-17 | — | — | US | disclosed |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN-CILAG (FR) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | HDAC3 193/4885HDAC4 1205/4885HDAC1 450/4885 |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR1I2, NR3C2 | HDAC3 143/4885HDAC4 974/4885HDAC1 364/4885 |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | HDAC3 193/4885HDAC4 1205/4885HDAC1 450/4885 |
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | NR1I3, NR3C2, NR1I2 | HDAC3 193/4885HDAC4 1205/4885HDAC1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.